Understanding the Grp94 Chaperone for Disease Treatment
Official title: Elucidating the Mechanistic Details of the Grp94 Molecular Chaperone through an Integrated Computational and Experimental Approach
Funded at Miami University Oxford · NIH-11123271 · Data updated 2026-11-12
This project aims to understand how a protein called Grp94 works inside our cells, which could help develop new treatments for diseases like diabetes, cancer, and heart conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Miami University Oxford NIH-funded |
| Lab location | 1 site (Oxford, United States) |
| Project start | August 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $343,784 |
| NIH project number | 5R35GM146963-04 |
| Project ID | NIH-11123271 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational research does not directly involve patient participation, but future clinical trials stemming from this work would likely target individuals with diseases linked to protein misfolding, such as type 2 diabetes, cancer, or neurodegenerative conditions.
✕Less likely to help
Patients seeking immediate treatment options would not directly benefit from this basic science project, as its goal is to understand fundamental mechanisms rather than to test new therapies.
What this research studies
Our cells rely on special proteins called chaperones, like Grp94, to correctly fold other proteins, which is essential for cell health. When Grp94 doesn't work right, it can lead to serious health problems such as type 2 diabetes, various cancers, and heart or brain diseases. This research uses both computer models and lab experiments to uncover the exact steps Grp94 takes to do its job. By learning these fundamental details, we hope to find better ways to design medicines that specifically target Grp94 to correct protein folding issues. This approach could lead to more effective treatments with fewer side effects than current options.
Why it matters
Potential benefit: If successful, this research could provide foundational knowledge for developing new, more targeted drugs to treat diseases caused by misfolded proteins, such as type 2 diabetes, cancer, and neurodegenerative disorders.
How similar studies have gone: While the Hsp90 superfamily of chaperones is well-studied, the specific mechanistic details of Grp94 are less understood, making this a novel approach to a promising drug target.
Where this research is happening
-
Miami University Oxford
Oxford, United States Active
Researchers
- Principal investigator: Kravats, Andrea N — Miami University Oxford
- Study coordinator: Kravats, Andrea N
Related research
Other NIH-funded projects on the same topics.
-
Nurse Practitioner Scope of Practice and Nursing Home Quality
This grant looks at how nurse practitioner regulatory rules affect staffing in nursing homes and the care residents receive.
-
How X chromosome differences may influence alcohol drinking in mice
This project looks at how sex chromosomes, especially the X chromosome, might affect alcohol drinking behavior and related brain signals in mice, with the goal of informing human understanding and future therapies.
-
ApoA4 and sympathetic signals to improve fat metabolism in obesity
A researcher team will study how apolipoprotein A4 (APOA4) affects fat tissue and liver metabolism through the body’s sympathetic nervous system, with a focus on adults with obesity.
-
Understanding how the Grp94 protein helps keep cells healthy and how to target it safely
Researchers are studying the Grp94 protein to learn how it helps proteins fold correctly in cells, with implications for diabetes, cancer, heart, and brain diseases.
-
Roadmap to unlock RPE plasticity for retinal regeneration
A research project aims to understand how retinal pigment epithelium (RPE) cells can be reprogrammed to become neural retina, with the goal of helping people with degenerative retinal diseases.
-
Understanding how newt iris cells can become lens tissue to guide eye healing
Scientists are studying how a special kind of salamander-like newt can repair its eye lens by reprogramming iris cells, in the hope of finding new ways to treat human eye diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.